In memoriam: Dr. Karel De Beule

In Memoriam: Karel De Beule
In Memoriam: Karel De Beule

Post provided by Dr. Beule’s colleagues at Tibotec.

In memoriam: Karel De Beule, PharmD, MBA (July 8, 1958 – April 6, 2010) following an outstanding 24+ year career in the pharmaceutical industry; Karel will be remembered for his contributions to pharmaceutical development in the infectious disease area, starting with the Janssen Pharmaceutica antifungal portfolio, which included itraconazole in the 1980-90’s, followed by his involvement from 2004 to 2010 with the novel TB drug, TMC 207, as compound development team leader at Tibotec. He was instrumental in establishing the landmark collaboration between Tibotec and the TB Alliance to accelerate TB drug development.

His unwavering dedication to the TB field will be remembered and sorely missed.

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...